Concepedia
Statistics
Publications
24
Citations
1.2K
H-Index
20
Active since
1988
Affiliations
University of Kentucky(Current)
Markey Cancer Center
University of California, Davis
Michael F. Daily is an author at University of Kentucky specializing in medicine, oncology, and liver disease.
Publications per year
1988–2017
PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways.
Roberto Gedaly, Paul Angulo, Jonathan Hundley et al. · PubMed · 2010 · 144 citations · Full text
Medicine, Oncology, Pharmacology +17
Predictors of surgical site infection after liver resection: a multicentre analysis using National Surgical Quality Improvement Program data
A. Moreno Elola-Olaso, Daniel L. Davenport, Jonathan Hundley et al. · HPB · 2011 · 119 citations · Full text
Medicine, Perioperative Medicine, Surgery +16
Targeting the Wnt/β-Catenin Signaling Pathway in Liver Cancer Stem Cells and Hepatocellular Carcinoma Cell Lines with FH535
Roberto Gedaly, Roberto Galuppo, Michael F. Daily et al. · PLoS ONE · 2014 · 118 citations · Full text
Medicine, Cancer Biology, Oncology +17
Long-term outcome of patients undergoing liver transplantation for mixed hepatocellular carcinoma and cholangiocarcinoma: an analysis of the UNOS database
Valery Vilchez, Malay B. Shah, Michael F. Daily et al. · HPB · 2016 · 105 citations · Full text
Medicine, Oncology, Surgery +15
PKI-587 and Sorafenib Targeting PI3K/AKT/mTOR and Ras/Raf/MAPK Pathways Synergistically Inhibit HCC Cell Proliferation
Roberto Gedaly, Paul Angulo, Jonathan Hundley et al. · Journal of Surgical Research · 2011 · 96 citations
Medicine, Oncology, Pharmacology +12
1–5 of 24